Fractyl Health Inc

NASDAQ:GUTSUnited States

Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and obesity. The Revita DMR System (Revita), the Company’s lead product candidate, is an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The Revita system is designed to enable durable and repeatable metabolic improvement via hydrothermal ablation of the dysfunctional duodenal mucosa to address duodenal pathology and consequent metabolic disease progression directly. The Company is involved in enrolling is pivotal Revitalize-1 study in patients with inadequately controlled T2D. It is also developing Rejuva, a locally administered, adeno-associated virus (AAV), delivered pancreatic gene therapy (PGTx), platform. Rejuva is designed to enable long-term remission of T2D and obesity.

Contact Information

Headquarters

3 Van De Graaff Drive, Suite 200BURLINGTON, MA, United States 01803

Phone

781-902-8800

Fax

302-655-5049

Executives

Independent Chairman of the Board

Allan Will

President, Co-Founder, Chief Product Officer

Jay Caplan

Chief Executive Officer, Co-Founder, Director

Harith Rajagopalan

Chief Financial Officer, Treasurer

Lisa Davidson

Chief Scientific Officer

Timothy Kieffer